EDX Medical Group Plc

Board/Management Information • Feb 14, 2025

National Storage Mechanism | Additional information

RNS Number : 0899X

EDX Medical Group PLC

14 February 2025

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended.  On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

14 February 2025

EDX Medical Group plc

AQSE: EDX

("EDX Medical" or the "Group" or "Company")

APPOINTMENT OF DIRECTOR & DEPUTY CHAIR

CAMBRIDGE, UK:  EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, cardiovascular and infectious diseases, announces today the appointment of Martin Walton as a board director and deputy chair of the Group.

Martin Walto n's appointment was approved in a resolution passed by the EDX Medical board of directors on Wednesday February 12.

Martin Walton has more than 35 years ' experience in finance and investment, including 15 years working with global life sciences companies.  He has completed multiple corporate transactions from spin-outs, seed- and growth- capital raises to MBOs, M&A, public market listings and sales to strategic and private equity buyers.

Jason Holt, chair of EDX Medical, commented: " We are very pleased to welcome someone of Martin ' s experience and expertise as deputy chair. He will be a great asset to the company. This year is extremely important in the development of the company as we continue to implement our business strategy through commercialisation and expansion of our product portfolio and the further development of sector partnerships. Martin will play a leading role in evaluating future strategic growth opportunities including consideration of progression to other public markets including the AIM market in London and a Hong Kong listing."

Professor Sir Chris Evans, OBE, founder of EDX Medical, said: "Martin and I have worked together closely for more than 22 years on multiple successful fund raisings and biotech transactions. Martin's long experience in various public markets will certainly benefit the company as we take forward our ambitious plans for the future."

Martin Walton said: "I am delighted to join the board of EDX Medical - a highly promising company - and to work again with Chris and the team. I will play an active role in helping drive forward our strategy to become an eminent developer and supplier of class-leading digital diagnostics. There is clear demand and need for earlier detection of disease and intervention on a global scale as well as providing the most advanced data driven solutions."

In accordance with Aquis Rule 4.9, Martin Walton has declared the following information. No other information is required to be disclosed.

Directorships:

Current	Commencement date	Role
Bradshaw Consulting Ltd	Feb 2014	Chairman & CEO
Interrad Medical LLC	Dec 2014	Non-executive
Excalibur Medicines Ltd	Mar 2020	Executive director
ReNeuron plc	Mar 2024	Non-executive
Past	Termination date
MaxRSVentures plc	Mar 2024	Non-executive
Liverpool Life Sciences Accelerator Partnership	Sept 2022	Non-executive (pro bono)
Iatros Capital Limited	Feb 2021	Non-executive
Igraine Ltd	Dec 2021	Director
Administration/Liquidations	Date	Event
Reneuron plc (Administration)	Mar 2024	Administration
SG Living	2012	Dissolved via voluntary strike-off
Picturesoft (UK) Ltd	Oct 2012	Dissolved via voluntary strike-off

The board of directors of EDX Medical plc accept responsibility for this announcement.

ENDS

Contacts

EDX Medical Group Plc
Dr Mike Hudson (Chief Executive Officer)	+44 (0)7812 345 301
Oberon Capital
Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking)	+44 (0)20 3179 5300
IFC Advisory (Investor Relations)
Tim Metcalfe	+44 (0)20 3934 6630
Graham Herring
Media House International
Ramsay Smith Gary McQueen	+44 (0)7788 414856 [email protected] + 44 (0)7834 694609 [email protected]

Notes for Editors:

About EDX Medical Group plc

The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has a number of significant strategic partnerships including; a product technology collaboration with Thermo Fisher EMEA Ltd, a logistics partnership with Fedex and a distribution agreement with Caris Life Sciences inc, each world leaders in their respective fields.

www.edxmedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXKXLFFELLBBBE